Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection

Table 4 Baseline and post treatment NS3/4A-mutations among patients failing hepatitis C virus treatment

Genotype	Previouslytreated	HCV PI	Response totreatment	HIV PI	Pre-treatmentHCV VL	Baseline NS3/4A-mutations	Baselinefold-change	Post-treatmentNS3/4A-mutations	Post-treatmentfold change1
1a	Yes	Tela	Non-responder	Atazanavir	5.9	0		V36M, R155K	62
1a	Yes	Tela	Non-responder	0	5.8	0		V36M, R155K	62
1a	Yes	Tela	Breakthrough	Atazanavir	6.0	0		R155K	7.4
1a	Yes	Tela	Breakthrough	Atazanavir	6.5	0		V36M	6.8-10.0
1a	No	Tela	Breakthrough	Atazanavir	6.0	0		V36M, R155K	62
1b	Yes	Tela	Relapse	Atazanavir	6.4	I132V	1.8	I132V, V36A	7.4-7.5
1a	No	Tela	Relapse	0	6.3	I132V	1.8	I132V, V36A	7.4-7.5
1b	No	Tela	Relapse	0	4.9	I132V	1.8	I132V, V36A	7.4-7.5
1a	NA	Boce	Relapse	Darunavir	NA	NA	NA	T54S, R155K	8.5

¹Fold-change in EC₅₀ with regard to specific PI received. HCV: Hepatitis C virus; Tela: Telaprevir; Boce: Boceprevir; HIV PI: Human immunodeficiency virus protease inhibitor; NA: Data unavailable; VL: Viral load.